MapLight Therapeutics, Inc. (MPLT) company profile
Close on Nov 17, 2026Market cap $304.70MP/E –Yield –
About MapLight Therapeutics
Pharmaceutical Preparations, SIC 2834
MapLight Therapeutics is a clinical-stage biopharmaceutical company that develops circuit-specific therapies for debilitating central nervous system disorders. The company operates a discovery platform to identify neural circuits causally linked to diseases and target those circuits for therapeutic modulation. Its lead product candidate is ML-007C-MA, a fixed-dose combination combining a muscarinic agonist with a peripherally acting anticholinergic agent. Its development programs serve individuals suffering from psychiatric and neurological conditions, specifically patients with schizophrenia and Alzheimer's disease psychosis.
The organization's operations include multiple clinical studies evaluated in healthy participants and patients across Phase 1 and Phase 2 clinical trials. Geographically, the company is incorporated in Delaware and conducts its business within the United States. MapLight Therapeutics maintains its principal executive offices and headquarters in Redwood City, California.
Summary of the business section of MapLight Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MapLight Therapeutics, Inc.
- Headquarters
- Redwood City, CA
- Address
- 800 Chesapeake Drive 94063
- Phone
- (650) 839-4360
- Website
- maplightrx.com
- Employees
- 133, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- RSM US LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- MPLT
- Exchange
- Nasdaq
- IPO date
- Oct 27, 2025
- Shares outstanding
- 46M, Aug 7, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1770069
- CUSIP
- 56565P103
- ISIN
- US56565P1030
- FIGI
- BBG01JZ5DBQ0
- Share class FIGI
- BBG01JZ5DBS8
- EIN
- 83-2163243
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher A. Kroeger | Chief Executive Officer, Director | 1,297,099 |
| Anatol Kreitzer | Chief Discovery Officer | 168,678 |
| Jonathan Gillis | CAO and Interim CFO | 142,315 |
| James Woodruff Lillie | Chief Scientific Officer | 198,597 |
| Erin Pennock Foff | Chief Medical Officer | 296,906 |
| Kristopher Hanson | General Counsel | 128,024 |
| Vishwas Setia | Chief Financial Officer | 356,256 |
| Troy Cox | Director | 23,484 |
| George Pavlov | Director | 28,932 |
| Martin Babler | Director | 7,864 |
| Maria C. Walker | Director | 62,703 |
| Timothy John Garnett | Director | 67,581 |
| Nanna Liebach Luneborg | Director | 3,932 |
| Robert C. Malenka | Director | 348,138 |
| James D. Trenkle | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Christopher A. Kroeger, M.D. President and Chief Executive Officer | $655.25K | $12.30M | $12.32M | $331.00K | $19.33K | $25.62M | +192% |
| Vishwas Setia Chief Financial Officer | $432.29K | $3.20M | $2.37M | $183.00K | $19.15K | $6.20M | +102% |
| Erin Pennock Foff, M.D., Ph.D. Chief Medical Officer | $531.00K | $2.87M | $2.64M | $194.00K | $20.85K | $6.25M | +127% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 24, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 22, 2019 | Name change | Name changed from Alvarado Therapeutics, Inc. to MapLight Therapeutics, Inc. |
See a number that looks wrong?